Psilocybin patent fillings

        
1
Owner/AssigneePatent/Pub. No.TitlePriority DateStatusGeneral subject matter
2
1Lennham PharmaceuticalsUS11000534B1Deuterated derivatives of psilocybin and uses thereof2020-10-08Granted 2021-05-11Pharmaceutical compositions of deuterated psilocybin
3
2Orthogonal ThinkerWO2021188870A1Psilocybin and psilocin containing compositions and methods of using and making the same2020-03-20PublishedCompositions of psilocybin and/or psilocin and supplements, e.g., amino acids, vitamins, GABA, caffeine, resveratrol, herbs, ginsing, etc., and methods of using and making them
4
3CaaMTechWO2021188812A1Crystalline norpsilocin compounds2020-03-19PublishedNorpsilocin compounds (crystalline 4-HO-NMT freebase and fumarate, 4-HO-NMT fumarate), pharmaceutical compositions thereof, methods of their use
5
4CaaMTechWO2021188782A1Crystalline psilacetin derivatives2020-03-19PublishedCrystalline 4-acetoxy-substituted versions of psilocin analogs (4-AcO-MET and 4-AcO-MALT hydrofumarate, 4-AcO-DALT fumarate fumaric acid) and their use
6
5Bright Minds BiosciencesWO2021179091A13-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-HT2 receptor modulators2020-03-12PublishedPsilocin analogs that possess 5-HT2A and/or 5-HT2c selective receptor activity, but lack at least some of the undesirable characteristics of 5-HT2B-agonist related activities
7
6EleusisWO2021183490A1Methods and systems for enhancing clinical safety of psychoactive therapies2020-03-09PublishedMethods and systems for efficient monitoring and scalability of psychedelic therapy, for training clinical staff, and for enhancing safety through oversight of clinical practice
8
7Cure PharmaceuticalUS20210275618A1Method for obtaining an extract of a plant biomass2020-03-05Pending in USMethods for obtaining an extract using a supercritical fluid solvent system, where the extract is from plant biomass comprising both psilocybin mushrooms and cannabis
9
8Neonmind BiosciencesWO2021159213A1Method for producing an extract of mushrooom and mushroom extract made therefrom2020-02-12PublishedMethods of manufacturing a mushroom extract, including from Psilocybe mushroms, the mushroom extract itself, and pharmaceutical formulations
10
9Yale University, U.S. Dep't of Veterans AffairsUS20210236523A1Psychedelic treatment for headache disorders2020-02-05Pending in USTreating a headache disorder by administering psilocybin, LSD, mescaline, DMT, DOI, DOB, and analogs thereof
11
10Mindset PharmaWO2021155470Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders2020-02-04PublishedProdrugs and deuterated derivatives of psilocybin, and methods of treating CNS disease, disorder or condition and/or a neurological disease, disorder or condition
12
11Mindset PharmaWO2021155468Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders2020-02-04PublishedProdrugs and deuterated derivatives of psilocybin, and methods of treating CNS disease, disorder or condition and/or a neurological disease, disorder or condition
13
12Mindset PharmaWO20211554673-Pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders2020-02-04Published3-pyrrolidine-indole derivatives of psilocybin, and methods of treating CNS disease, disorder or condition and/or a neurological disease, disorder or condition
14
13Neonmind BiosciencesWO2021108911A1Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder2019-12-04Pending in USMethods of aiding weight loss, treating compulsive eating disorder and obesity, and altering the diet by administering psilocybin, psilocin, and analogs
15
14Paul StametsUS20210145851A1Tryptamine compositions for enhancing neurite outgrowth2019-11-19Pending in USNeurotrophic and nootropic compositions comprising tryptamines and other mushroom extracts, cannabinoids, as well as phenethylamines and amphetamines
16
15CB TherapeuticsUS20210147888A1Biosynthetic production of psilocybin and related intermediates in recombinant organisms2019-11-15Pending in USGenetically engineered host cells that produce psilocybin and method of their production
17
16Miami UniversityWO2021086513A1Methods for the production of psilocybin and intermediates or side products2019-10-28PublishedBiosynthetic methods, prokaryotic (bacterial) host cells, expression vectors, and kits for the production of psilocybin and its intermediates and side products
18
17Esolate LtdWO2021081138A1Compositions comprising superfine compounds and production thereof2019-10-21PublishedStable edible, inhalable, soluble, and drinkable pharmaceutical grade APIs, and methods for making them, including where the API is a psychedelic such as psilocybin or psilocin
19
18Tassili Life SciencesWO2021072530A1Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder2019-10-21PublishedControlled release formulations of psilocybin and psilocybe-derived agents, for alleviating symptoms of mTBI and PTSD
20
19Institute Of Science And Technology AustriaWO2021074448A1Stimulation of neuronal plasticity2019-10-18PublishedInducing synchronized gamma oscillations by applying a visual stimulus comprising a flashing light, together in some embodiments with a psychedelic including psilocybin
21
20Pure Laboratories LLCUS20210100741A1Flavored bioactive extracts and methods of flavor introduction2019-10-04Pending in USMethods of formulating a homogeneous flavored bioactive product by melting an extract, combining a flavoring and carrier, and cooling; the extracts include psilocybin
22
21Intima BioscienceWO2021067626A1Genetic engineering of fungi to modulate tryptamine expression2019-10-01PublishedMethods for modulating the psilocybin biosynthesis pathway and genetically modified organisms with induced and/or increased expression of psilocybin and psilocin
23
22Danmarks Tekniske UniversitetWO2021052989A1Yeast cells and methods for production of tryptophan derivatives2019-09-15PublishedTransformed cells capable of producing compounds including norbaeocystin, baeocystin, psilocybin, psilocin, aeruginascin, and methods of their use in production
24
23University of MarylandWO2021030571A1Methods of treating psychological and brain disorders2019-08-12PublishedMethods of treating a psychological disorder by administering a 5-HT agonist in combination with a 5-HT2A antagonist, the 5-HT agonists including psilocybin
25
24Tassili Life Sciences (Champignon Brands)WO2021016710Controlled release formulations of multiple active pharmaceutical agents, and psilocybe-derived agents in combination with cannabis-derived agents and methods for their use2019-07-30PublishedPsilocybe and cannabis derived compounds formulated in multiple layers to release the ingredients at different times, dosages and/or locations in body
26
25Concept Matrix SolutionsUS20210015833A1Oral soft gel capsule containing psychedelic compound2019-07-18Pending in USSoftgels containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations"
27
26Concept Matrix SolutionsUS20210015738A1Oral dissolvable film containing psychedelic compound2019-07-17Pending in USFilms containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations"
28
27Silo WellnessWO2021003467A1Metered dosing compositions and methods of use of psychedelic compounds2019-07-04PublishedCompositions of psychedelic compounds for use in metered-dosing administration modalities, such as a nasal spray or pressurized metered-dose inhaler
29
28Karl Dresdner, Michael Cary, Chase HudsonUS20200345585A1Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness2019-04-30Pending in USProcesses for making aqueous therapeutic nanoparticles, including with cannabinoids, psilocybin and related tryptamines, LSD, MDMA and MDA, ayahuasca, and ketamine
30
29Compass PathwaysWO2020212952A1Treatment of depression and other various disorders with psilocybin2019-04-17PublishedTreating depression, bipolar disorder, neurocognitive disorders, autism spectrum disorder, ADHD, and other disorders with psilocybin
31
30Compass PathwaysWO2020212951A1Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin2019-04-17PublishedTreating anxiety disorders, OCD, headache disorders, eating disorders, and their comorbidities with psilocybin
32
31Compass PathwaysWO2020212948A1Methods of treating neurocognitive disorders, chronic pain and reducing inflammation2019-04-17PublishedTreating neurocognitive disorders, Parkinsonian syndrome, epilepsy, sleep-wake disorders, chronic pain and reducing inflammation with psilocybin
33
32The Regents Of The University Of CaliforniaWO2020185581A2Compositions and methods for modulating lipid and steroid metabolism2019-03-08PublishedPromoting colonization of spore-forming bacteria in a patient’ s gut, by administering a serotonin receptor agonist, including psilocybin, psilocin, DMT, and 5-MeO-DMT
34
33University Of Padova, Institute For Research In Biomedicine, BarcelonaWO2020181194A1Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations2019-03-07PublishedStructural analogs of psilocin, norpsilocin, psilocybin, baeocystin, norbaeocystin, DOI, DMT, LSD, and ibogaine, and their use as neuroplastogens and for microdosing
35
34Diamond TherapeuticsWO2020157569A1Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders2019-01-30PublishedTreating a neurological condition by administration of a serotonin receptor agonist, including psilocybin, in an amount insufficient to cause a hallucinogenic effect
36
35Apollo NeuroscienceUS10974020Systems and methods of mitigating negative effects of therapies with transcutaneous vibration2019-01-04GrantedTranscutaneous vibratory simulation during psilocybin-assisted psychotherapy
37
36Palo Alto Investors LPUS20200179349A1Methods of Treating Food Allergy Conditions2018-12-06GrantedTreating a food allergy, by administration of a psychedelic, including dried psilocybin mushrooms and psychedelic tryptamines
38
37Yale University, U.S. Dep't of Veterans AffairsUS20210251969A1Combination therapy for treating or preventing depression or other mood diseases2018-08-20Pending in USTreating depression and mood disorders, with combination of a TOR inhibitor or immunosuppressant together with ketamine, psilocybin, LSD, ayahuasca, and DMT
39
38Applied Biology, Inc.WO2020023084A1Taar Receptor Agonists For The Treatment Of Alopecia2018-07-26PublishedMethods for treating hair shedding by applying a composition of a pilomotor effective amount of a Taar receptor agonist topically, including tryptamines and psilocin
40
39Robert PetcavichWO2019246532A1Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases2018-06-21PublishedTreating neurodegenerative disease by administration of a psychedelic, including psilocybin
41
40VTT Technical Research Centre of FinlandUS20210010015A1Heterologous production of psilocybin2018-03-19Pending in USBiosynthetic production of psilocybin from host cell
42
41New Atlas Biotechnologies LLCUS20210277433A1Processes for the production of tryptamines2018-03-08Pending in USTryptamine and ibogamine compounds, pharmaceutical compositions comprising them, and methods of using them to improve perception and mood
43
42New Atlas Biotechnologies LLCUS20210108238A1Processes for the production of tryptamines2018-03-08Pending in USProkaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives, including psilocybin
44
43Akili InteractiveWO2019161050A1Cognitive platform including computerized elements coupled with a therapy for mood disorder2018-02-18PublishedComputer systems for mood and cognitive assessment during psychedelic-assisted psychotherapy, including with psilocybin
45
44CaaMTechUS20190142851A1Compositions comprising a psilocybin derivative and a cannabinoid2017-11-16Pending in USPurified psilocybin derivatives combined with a cannabinoid
46
45Consejo Superior De Investigaciones Científicas (CSIC)WO2019081764A1Combination Product For The Treatment Of Neurological And/or Psychiatric Disorders2017-10-26PublishedCombination product comprising (1) psychedelic, including psilocybin and psilocin, and (2) a 5-HT2A receptor antagonist to prevent hallucinations
47
46EleusisWO2019079742A1Methods and systems for enhancing safety of psychedelic drug therapies2017-10-19PublishedScreening a candidate for treatment with psychedelic agent, including psilocybin
48
47Compass PathwaysUS10947259Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use2017-10-09Granted 2021-03-16 (expires 2038-10-09)Pharmaceutical compositions of crystalline psilocybin in the form Polymorph A, and methods of treating MDD
49
48Compass PathwaysUS20210155642Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use2017-10-09Published, allowedPharmaceutical compositions of crystalline psilocybin in the form Hydrate A, and methods of treating MDD
50
49Compass PathwaysUS10947257Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use2017-10-09Granted 2021-03-23 (expires 2038-10-09)Oral dosage forms of crystalline psilocybin in the form Polymorph A, and methods of treating MDD
51
50Compass PathwaysUS20200199161A1Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use2017-10-09Pending in USMethods for manufacturing psilocybin from psilocin at greater than 100g scale
52
51Compass PathwaysUS10519175B2Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use2017-10-09Granted 2019-12-31 (expires 2038-10-09)Treating drug resistant depression with crystalline psilocybin in the form Polymorph A
53
52Sensory Design & Technology LtdUS20200211703A1Liquid dispensing system creating and maintaining a personalised bubble with a defined radius and concentration2017-07-29Pending in USWearable devices that dispense controllable volumes of liquids such as perfume, but that also can be used for microdosing psychedelic medicines such as LSD and psilocybin
54
53Timothy Foster and Charles NicholsUS20200330405A1Compositions and methods for treating ocular pathologies2017-05-01Pending in USMethods of treating an eye condition using a serotonin 2A receptor agonist, including a psychedelic
55
54EleusisUS20200147038A1Assessing and treating psychedelic-responsive subjects2017-04-20Pending in USImproving mental or physical well-being by administration of a psychedelic, including psilocybin
56
55CaaMTechUS20210085671A1Compositions and methods comprising a combination of serotonergic drugs2017-02-09Pending in USCombinations of two serotonergic drugs, including psilocybin derivatives, tryptamines, cannabinoids, SSRIs, LSD, and MDMA, and use to treat psychological disorders
57
56CaaMTechUS10933073B2Compositions and methods comprising a psilocybin derivative2017-02-09Granted 2021-03-02 (expires 2038-09-11)Dosage formulations comprising certain psilocybin derivatives and cannabinoids
58
57Procare BeheerUS10729706B2Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes2017-01-18Granted 2020-08-04 (expires 2038-01-18)Treating a psychological disorder by administration of psilocybin together with a cannabinoid and/or a terpene
59
58Joseph RustickUS10596378B2Method for treatment of depression using synaptic pathway training2016-10-18Granted 2020-03-24 (expires 2038-06-07)Treating a neurologic condition by synaptic pathway training, including by administration of psilocybin
60
59Insectergy LLCUS11180781B2Biosynthetic cannabinoid production methods2016-08-21Granted 2021-11-23Distilled compositions comprising a mixture of biosynthetic and non-biosynthetic cannabinoids, some further comprising psilocybin
61
60Insectergy LLCUS10738268B2Cannabis nanoemulsion methods2016-08-21Granted 2020-08-11 (expires 2036-11-01)
Methods to produce cannabis oil nanoemulsions with various compounds including psilocybin
62
61Paul StametsUS20210251976A1Tryptamine compositions for enhancing neurite outgrowth2016-07-23Pending in USMethods of treating or improving a mental health disorder by administering up to 10 mg psilocybin or up to 0.3 g psilocybin containing mushrooms
63
62Paul StametsUS20210069170A1Tryptamine compositions for enhancing neurite outgrowth2016-07-23Pending in USNeurotrophic and nootropic compositions comprising psilocybin and other mushroom extracts, cannabinoids, as well as phenethylamines and amphetamines
64
63Paul StametsUS20200375967Compositions of psilocybin and analogs2016-07-23Pending in USCompositions of psilocybin, niacin, and mushroom or cannabis extracts, and their use to treat neurological or mental health disorders
65
64Paul StametsUS20190192498A1Psilocybin compositions2016-07-23Pending in USCompositions of psilocybin, niacin, and mushroom or cannabis extracts, and their use to treat neurological or mental health disorders
66
65Paul StametsUS20190105313A1Psilocybin compositions2016-07-23Pending in USCompositions of psilocybin, niacin, and mushroom or cannabis extracts, and their use to treat neurological or mental health disorders
67
66Paul StametsUS20180021326A1Compositions and methods for enhancing neuro- regeneration and cognition by combining mushroom extracts containing [] psilocin or psilocybin with erinacines or hericenones enhanced with niacin2016-07-23AbandonedCompositions of psilocybin, niacin, and mushroom or cannabis extracts, and their use to improve neurological health
68
67Syqe MedicalUS10118006B2Methods, devices and systems for pulmonary delivery of active agents2014-06-30Granted 2018-11-06 (expires 2035-06-30)Metered dose inhalers that monitor effects and their use to deliver pharmaceutically active agents including cannabinoids, salvinorin A, cocaine, DMT, and psilocybin
69
68Paul StametsUS20200376055A1Integrative fungal solutions for protecting bees2014-03-10Pending in USCompositions for improving bee health and for preventing and treating colony collapse disorder comprising mycelium extracts, including from Psilocybe spp.
70
69Syqe MedicalUS11071712B2Method and system for drug delivery2010-12-22Granted 2021-07-27Drug dose structure for use with an inhaler device having source material from which at least one active substance is released for delivery by vaporization, including psilocybin
71
70Syqe MedicalUS9775379B2Method and system for drug delivery2010-12-22Granted 2017-10-03
(expires 2034-09-26)		Inhaler device for controlled extraction of at least one active substance from at least one type of plant matter by application of heat, including psilocybin
72
71Emory UniversityUS20120108510A1Methods of improving behavioral therapies2010-05-20AbandonedPsychedelic-assisted psychotherapy using an oxytocin releasing agent, including psilocybin
73
72Galenea CorpUS20120159656A1Compositions and methods for evaluating cognitive defects2009-04-24AbandonedUsing psilocybin to identify a candidate therapeutic agent for treatment of a cognitive deficit
74
73Pisgah LabsUS20080293695A1Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance2007-05-22AbandonedDrug substances that can be administered therapeutically but having anti-abuse properties when used non-therapeutically, the substances including psilocybin and psilocin
75
74Koninklijke DSM (formerly Microbia Inc)US7229784B2Modulation of secondary metabolite production by zinc binuclear cluster proteins2000-09-19Granted 2007-06-12 (expires 2023-06-05)Improving yield of fungal metabolites in bioengineered cells, including psilocybin
76
75SandozUS3192111AMethod of inducing therapeutic tranquilization with psilocybin and psilocin1959-02-16Granted 1965-06-29 (expired 1982-06-29)Using psilocybin and psilocin to induce tranquilization
77
76SandozUS3075992AEsters of indoles1958-09-12Granted 1963-01-29 (expired 1980-01-29)Discloses, with coinventor Franz Troxler, the first laboratory synthesis of psilocybin and various analogues; claims novel analogues
78
77SandozUS3183172AObtaining psilocybin and psilocin from fungal material1958-02-21Granted 1965-05-11 (expired 1982-05-11)Extracting psilocybin and psilocin from fungal material
Top